MMP11 and melanoma: MMP11-high patients exhibited a trend toward prolonged overall survival (OS) in both melanoma (HR = 0.62, 95% CI 0.37–1.04, P = 0.07) and clear cell renal carcinoma (HR = 0.64, 95% CI 0.33–1.31, P = 0.19) cohorts (Supplementary Figures S2D, E).